Posted on 03/09/2009 in Pharmaceutical Company Product News Servier has pointed out the positive results of a new study involving one of its products - Procoralan (ivabradine).
The company points to research unveiled at the European Society of Cardiology this week that shows ivabradine reduces the risk of heart attacks in patients suffering from angina.
According to the results, people with angina with a resting heart rate of greater than 70 beats per minute (bpm) benefit the most from taking ivabradine and this reduces their risk of a heart attack by 73 per cent, regardless of their existing medication.
"This is very important as previous data shows that a faster resting heart rate (greater than 70 bpm) combined with coronary artery disease significantly increases the risk of heart attacks even with standard treatment."
In March, Servier expressed satisfaction at a court ruling ordering the National Institute for Health and Clinical Excellence to re-evaluate its guidance for the prevention of osteoporotic fragility fractures in postmenopausal women.
Other news stories from 03/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
